AMR: ENABLE selects Mutabilis candidate

  07 November 2019

A new oral combination treatment that might overcome  beta-lactam / fluoroquinolone co-resistance has now been selected for accelerated preclinical development by the Portfolio Management Committee of ENABLE, a programme under the Innovative Medicines Initiative’s (IMI) New Drugs 4 Bad Bugs (ND4BB) portfolio.

Further reading: European Biotechnology
Author(s): tg
Smart Innovations  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

LifeArc

Antimicrobial Resistance Fighter Coalition

Bangalore Bioinnovation Centre

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS





Ambassador Network

Join the AMR Insights Ambassador Network today!

Connect to over 650 AMR professionals and students in 65 countries!

Register

What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!

Keep me informed